Get the Stockscreener App
4.99
0.20%
0.010
Pre-market:
4.99
2 Seventy Bio Inc stock is traded at $4.99, with a volume of 287.06K.
It is up +0.20% in the last 24 hours and up +0.81% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$4.98
Open:
$4.98
24h Volume:
287.06K
Relative Volume:
0.24
Market Cap:
$261.17M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-1.6254
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
+0.00%
1M Performance:
+0.81%
6M Performance:
+0.20%
1Y Performance:
+17.27%
1-Day Range:
$4.98
$4.99
1-Week Range:
$4.97
$4.99
52-Week Range:
$2.29
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
4.99 | 261.17M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Downgrade | Goldman | Neutral → Sell |
| Jan-31-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-31-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-30-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| May-02-22 | Initiated | Goldman | Buy |
| Feb-10-22 | Initiated | SVB Leerink | Outperform |
| Jan-06-22 | Initiated | Cowen | Outperform |
| Nov-09-21 | Initiated | Canaccord Genuity | Buy |
| Nov-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
Bristol Myers Squibb to Acquire 2seventy bio for $5.00 Cash Per Share: Q4 Results Released - Stock Titan
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):